$9.72
7.64% day before yesterday
Nasdaq, Jan 02, 10:16 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US88688T1007
Symbol
TLRY

Tilray, Inc. Series 2 Stock price

$9.72
+2.01 26.07% 1M
+4.87 100.33% 6M
+0.69 7.64% YTD
-4.88 33.42% 1Y
-17.18 63.87% 3Y
-80.28 89.20% 5Y
-214.18 95.66% 10Y
-214.18 95.66% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.69 7.64%
ISIN
US88688T1007
Symbol
TLRY
Industry

New AI Insights on Tilray, Inc. Series 2 Insights AI Insights on Tilray, Inc. Series 2

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$1.2b
Net debt
$33.6m
Cash
$264.8m
Shares outstanding
111.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.4 | 1.3
EV/Sales
1.4 | 1.3
EV/FCF
negative
P/B
0.7
Financial Health
Equity Ratio
72.9%
Return on Equity
-144.7%
ROCE
-5.3%
ROIC
-5.3%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$830.8m | $881.1m
EBITDA
$-25.0m | $65.4m
EBIT
$-95.7m | $-36.1m
Net Income
$-2.1b | $-57.6m
Free Cash Flow
$-96.3m
Growth (TTM | estimate)
Revenue
2.3% | 7.3%
EBITDA
59.7% | 440.8%
EBIT
34.6% | 66.5%
Net Income
-910.2% | 97.4%
Free Cash Flow
-17.2%
Margin (TTM | estimate)
Gross
28.7%
EBITDA
-3.0% | 7.4%
EBIT
-11.5%
Net
-258.5% | -6.5%
Free Cash Flow
-11.6%
More
EPS
$-20.3
FCF per Share
$-0.9
Short interest
16.4%
Employees
3k
Rev per Employee
$310.0k
Show more

Is Tilray, Inc. Series 2 a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Tilray, Inc. Series 2 Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Tilray, Inc. Series 2 forecast:

7x Buy
44%
8x Hold
50%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Tilray, Inc. Series 2 forecast:

Buy
44%
Hold
50%
Sell
6%

Financial data from Tilray, Inc. Series 2

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Aug '25
+/-
%
831 831
2% 2%
100%
- Direct Costs 592 592
3% 3%
71%
238 238
0% 0%
29%
- Selling and Administrative Expenses 256 256
2% 2%
31%
- Research and Development Expense 0.22 0.22
67% 67%
0%
-25 -25
60% 60%
-3%
- Depreciation and Amortization 71 71
16% 16%
9%
EBIT (Operating Income) EBIT -96 -96
35% 35%
-12%
Net Profit -2,148 -2,148
910% 910%
-259%

In millions USD.

Don't miss a Thing! We will send you all news about Tilray, Inc. Series 2 directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tilray, Inc. Series 2 Stock News

Positive
The Motley Fool
2 days ago
Cannabis stocks have had significant momentum due to positive regulatory changes in the U.S. However, this momentum is likely to be relatively short-lived. These 10 Stocks Could Mint the Next Wave of Millionaires ›
Neutral
MarketBeat
4 days ago
On Dec. 18, 2025, President Trump signed a pivotal Executive Order directing the Attorney General to expedite the rescheduling of cannabis. By all traditional metrics, this political victory should have sparked a sustained rally.
Negative
WSJ
4 days ago
Stocks took a surprise tumble after the White House moved to reclassify marijuana as a less dangerous drug.
More Tilray, Inc. Series 2 News

Company Profile

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Head office United States
CEO Irwin Simon
Employees 2,650
Founded 2018
Website www.tilray.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today